menu
    • menu
    [{"orgOrder":0,"company":"Children\u2019s Hospital Los Angeles","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Lorazepam","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Children\u2019s Hospital Los Angeles","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"","sponsorNew":"Children\u2019s Hospital Los Angeles \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"Children\u2019s Hospital Los Angeles \/ National Institutes of Health"}]

    Find Clinical Drug Pipeline Developments & Deals for (+/-)-Lorazepam

    Menu

    (+/-)-Lorazepam

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Children’s Hospital Los Angeles

                            Country arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Children’s Hospital Los Angeles

                            Country arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lorazepam,Tofacitinib Citrate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : National Institutes of Health

                            Deal Size : $5.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Children’s Hospital Los Angeles to Launch $5.3 Million NIH Study for First Clinical Trial for Down Syndrome ...

                            Details : The funding will be used in the randomized controlled trial which will investigate the safety and effectiveness of three different treatments for Down syndrome regression disorder. Lorazepam is an anti-anxiety medication that treats catatonia and other s...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 25, 2023

                            Lead Product(s) : Lorazepam,Tofacitinib Citrate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : National Institutes of Health

                            Deal Size : $5.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth